A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
Clinical trial NCT07614776 · RECRUITING
Trial details
- NCT number
- NCT07614776
- Sponsor
- Amgen
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-05-27
- Primary completion
- 2027-07-31
- Enrollment
- 304
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.